Momelotinib Hits the Mark for Deadly Bone Marrow Cancer

The investigational drug has shown benefits in myelofibrosis in a new phase 3 trial with a new sponsor, which plans to apply for FDA approval.
Medscape Medical News

source https://www.medscape.com/viewarticle/975651?src=rss

Comments

Popular posts from this blog

New AAFP practice guideline sets blood pressure targets for adults with hypertension